For how we live.
AMPLIFIED enriched for early rheumatoid arthritis patients thought to respond best to abatacept, then compared it head-to-head with adalimumab. At week 24 the two drugs were indistinguishable.
Lorecivivint improved pain modestly and changed nothing structural. Sprifermin grew cartilage and the effect made no difference by year five. Both illustrate the gap between a biomarker and a benefit.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.